This bias is reinforced by the marketing message of pharmaceutical companies to physicians, which has emphasized research on delayed diagnosis and under-recognition of bipolar disorder, possibly sensitizing clinicians accordingly.
Ce travers est renforcé par la communication des entreprises pharmaceutiques en direction des médecins, car elle met en avant les études sur le retard au diagnostic et la sous-reconnaissance des troubles maniaco-dépressifs, ce qui sensibilise les cliniciens.